A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy

This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form of a gene called BRAF. They are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving vemurafenib and cobimetinib may work better to treat patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.

Start Date30 Nov 2024

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06008119 / Not yet recruitingPhase 3

A Multicenter, Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

This is a multicenter, randomized, open-label, 3-arm Phase 3 study

Start Date24 Nov 2023

Sponsor / Collaborator

Shanghai Kechow Pharma, Inc.Startup

CTR20232218 / RecruitingPhase 3

一项评价妥拉美替尼联合维莫非尼治疗BRAFV600E突变转移性结直肠癌患者有效性和安全性的随机、对照、开放性、多中心Ⅲ期临床研究

[Translation] A randomized, controlled, open-label, multicenter phase III clinical study to evaluate the efficacy and safety of tolametinib combined with vemurafenib in the treatment of patients with BRAFV600E mutation metastatic colorectal cancer

比较妥拉美替尼联合维莫非尼与研究者选择治疗（以化疗为基础）的有效性，基于独立影像评估委员会（IRRC）评估确定的无进展生存期（IRRC-PFS）。

[Translation]

To compare the effectiveness of tolametinib plus vemurafenib with investigator's choice of treatment (chemotherapy-based), based on progression-free survival determined by independent radiographic review committee (IRRC) assessment (IRRC-PFS).

Start Date16 Oct 2023

Sponsor / Collaborator

Shanghai Kechow Pharma, Inc.Startup

[+1]

100 Clinical Results associated with Vemurafenib

100 Translational Medicine associated with Vemurafenib

100 Patents (Medical) associated with Vemurafenib

2,510

Literatures (Medical) associated with Vemurafenib

01 Jan 2024·Journal of cancer research and clinical oncology

Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study

Article

Author: Wang, Wenxia ; Ma, Yuhan ; He, Xiangling ; Yang, Lihua ; He, Yunyan ; Lin, Danna ; Wang, Zhixuan ; Zhu, Chengguang ; Lei, Jiaying ; Weng, Wenjun ; Li, Yang ; Liu, Xiaoshan ; Jia, Wenguang

Abstract:

Background:

Langerhans cell histiocytosis (LCH) is a myeloid neoplasia with potentially fatal consequences, and about 2/3 of cases involve the BRAFV600E kinase-activated mutation. Vemurafenib, a BRAF inhibitor, has demonstrated significant clinical improvements in LCH. However, the high relapse rate of LCH following cessation of vemurafenib therapy remains a major challenge, and alternative treatment strategies require further investigation.

Methods:

In this retrospective multi-center study, we evaluated the efficacy and safety of vemurafenib combined with conventional chemotherapy in patients with severe or refractory LCH.

Results:

Seventeen patients were enrolled in the study, with eleven classified as risk organ involvement (RO +). Six received the combination therapy as the primary treatment, and eleven after being refractory to prior chemotherapy. The overall response rate was 94.1%. Progression-free survival among all 17 patients was 70.6% (12/17) at a median follow-up of 32 months, and relapse-free survival among the 15 patients with discontinuation after a response was 73.3%(11/15) at a median follow-up of 34 months. Five of six patients (83.3%) with myeloid BRAFV600E mutations demonstrated molecular remission. The overall survival rate was 100%. Adverse events were mostly classified as grades 1 or 2.

Conclusion:

Our data suggest that the combination of vemurafenib and chemotherapy can achieve sustained clinical and molecular level relief in children with LCH, and side effects are tolerable.

15 Mar 2024·International journal of cancer

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanisms

Article

Author: Müller, Anja ; Niessner, Heike ; Sergon, Mildred ; Lesche, Mathias ; Seliger, Barbara ; Tunger, Antje ; Karitzky, Paula C ; Dinter, Lisa ; Schmitz, Marc ; Meier, Friedegund ; Wehner, Rebekka ; Käubler, Theresa ; Wurm, Alexander A ; Mehnert, Marie-Christin ; Dahl, Andreas ; Westphal, Dana ; Beissert, Stefan ; Schulz, Alexander

Abstract:

About 25% of melanoma harbor activating NRAS mutations, which are associated with aggressive disease therefore requiring a rapid antitumor intervention. However, no efficient targeted therapy options are currently available for patients with NRAS‐mutant melanoma. MEK inhibitors (MEKi) appear to display a moderate antitumor activity and also immunological effects in NRAS‐mutant melanoma, providing an ideal backbone for combination treatments. In our study, the MEKi binimetinib, cobimetinib and trametinib combined with the BRAF inhibitors (BRAFi) encorafenib, vemurafenib and dabrafenib were investigated for their ability to inhibit proliferation, induce apoptosis and alter the expression of immune modulatory molecules in sensitive NRAS‐mutant melanoma cells using two‐ and three‐dimensional cell culture models as well as RNA sequencing analyses. Furthermore, NRAS‐mutant melanoma cells resistant to the three BRAFi/MEKi combinations were established to characterize the mechanisms contributing to their resistance. All BRAFi induced a stress response in the sensitive NRAS‐mutant melanoma cells thereby significantly enhancing the antiproliferative and proapoptotic activity of the MEKi analyzed. Furthermore, BRAFi/MEKi combinations upregulated immune relevant molecules, such as ICOS‐L, components of antigen‐presenting machinery and the “don't eat me signal” molecule CD47 in the melanoma cells. The BRAFi/MEKi‐resistant, NRAS‐mutant melanoma cells counteracted the molecular and immunological effects of BRAFi/MEKi by upregulating downstream mitogen‐activated protein kinase pathway molecules, inhibiting apoptosis and promoting immune escape mechanisms. Together, our study reveals potent molecular and immunological effects of BRAFi/MEKi in sensitive NRAS‐mutant melanoma cells that may be exploited in new combinational treatment strategies for patients with NRAS‐mutant melanoma.

01 Feb 2024·Clinical nuclear medicine

The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?

Article

Author: de Wit-van der Veen, Linda J ; Hospers, Geke A P ; Lopez-Yurda, Marta ; Boellaard, Ronald ; van der Veldt, Astrid A M ; Kapiteijn, Ellen W ; Stokkel, Marcel P M ; van den Eertwegh, Alfons J M ; Haanen, John B A G ; Aalbersberg, Else A ; de Vos, Filip Y F L ; van der Hiel, Bernies ; Boers-Sonderen, Marye J ; Aarts, Maureen J B ; de Groot, Jan Willem B

Purpose:

The aims of this study were to investigate whether (early) PERCIST response monitoring with 18F-FDG PET/CT is predictive for progression-free survival (PFS) in unresectable stage III or IV melanoma patients treated with BRAF/MEK inhibitor (MEKi) and to define dissemination patterns at progression with a lesion-based evaluation in direct comparison to baseline to improve our understanding of 18F-FDG PET/CT during BRAF/MEKi.

Patients and Methods:

This prospective multicenter single-arm study included 70 patients with unresectable stage III/IV BRAF-mutated melanoma who underwent contrast-enhanced CT and 18F-FDG PET/CT at baseline and 2 and 7 weeks during treatment with vemurafenib plus cobimetinib and at progression if possible. Tumor response assessment was done with RECIST1.1 and PERCIST. Follow-up PET/CT scans were visually compared with baseline to assess dissemination patterns.

Results:

Using RECIST1.1, PFS was not significantly different between the response groups (P = 0.26). At 2 weeks, PERCIST median PFS was 15.7 months for patients with complete metabolic response (CMR) versus 8.3 months for non-CMR (P = 0.035). The hazards ratio (HR) for progression/death in non-CMR versus CMR was 1.99 (95% confidence interval [CI], 1.03–3.84; P = 0.040) and 1.77 (95% CI, 0.91–3.43; P = 0.0935) when adjusting for lactate dehydrogenase (LDH). At 7 weeks, median PFS for PERCIST CMR was 16.7 months versus 8.5 months for non-CMR (P = 0.0003). The HR for progression/death in the non-CMR group was significantly increased (HR, 2.94; 95% CI, 1.60–5.40; P = 0.0005), even when adjusting for LDH (HR, 2.65; 95% CI, 1.43–4.91; P = 0.0020). At week 7, 18F-FDG PET/CT was false-positive in all 4 (6%) patients with new FDG-avid lesions but CMR of known metastases. When 18F-FDG PET/CT was performed at progressive disease, 18/22 (82%) patients had progression of known metastases with or without new 18F-FDG–avid lesions.

Conclusions:

This study shows that PERCIST response assessment at week 7 is predictive for PFS, regardless of LDH. At 2 weeks, patients with CMR have longer PFS than patients with non-CMR, but different PET parameters should be investigated to further evaluate the added value of early 18F-FDG PET/CT. Disease progression on PET/CT is predominated by progression of known metastases, and new 18F-FDG–avid lesions during BRAF/MEKi are not automatically a sign of recurrent disease.

News (Medical) associated with Vemurafenib

18 Dec 2023

·www.globenewswire.com

Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors

Co-founder and former CEO of Plexxikon brings a proven track record of building platform-based companies and delivering novel medicines to patientsPARIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced the appointment of Dr. K. Peter Hirth to its Board of Directors. Dr. Hirth brings 30 years of biotech leadership and expertise in biotechnology and pharmaceutical discovery and development. He replaces Dr. Roger J. Garceau, who has stepped down from the Board. "We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome. "Peter is a recognized leader in the biotech industry and his extensive experience in corporate strategy and drug development will be invaluable to Enterome’s future growth and success. We look forward to Peter’s guidance as we execute on our vision to bring OncoMimics™ based immunotherapies to patients in need. I’d also like to thank Roger for his invaluable contributions to Enterome during his time on the Board." Dr. Hirth possesses a wealth of experience and an exceptional track record in the biopharmaceutical industry. Currently, he serves as the Chairman of the Board of IO Biotech and as a Director on the boards of Vaxcyte, Trex Bio, and Aligos Therapeutics. In addition, he acts as an Advisor to Wellington Partners, a global venture capital firm. Previously, Dr. Hirth served as CEO and co-founder of Plexxikon from 2001 to 2013, where he led the development of a novel, structure-guided drug discovery platform, resulting in several new chemical entities entering clinical trials, including Zelboraf®, an FDA-approved therapy for metastatic melanoma. Before Plexxikon, Dr. Hirth was President and co-founder of Sugen, a company that went public on Nasdaq in 1994 and was later acquired by Pharmacia/Pfizer. During his tenure, he played a pivotal role in building the company and advancing several kinase inhibitors through clinical trials in oncology. Notably, Sutent®, a drug for the treatment of a type of gastrointestinal cancer, was subsequently approved for human use. Dr. Hirth also served as Vice President of Research at Boehringer Mannheim, where he successfully led the company’s erythropoietin program to approval. He started his career as a research scientist with the Max Planck Institutes. Dr. Hirth received his PhD in Molecular Genetics from Heidelberg University, Germany, and completed his post-doctoral work at the University of California, San Diego. Dr. Hirth commented: "I am honored to join Enterome at this exciting time. The emerging clinical data from the OncoMimics™ pipeline continue to demonstrate strong, durable, and target-specific immune responses associated with positive clinical outcomes in various oncologic indications. I eagerly anticipate contributing to Enterome’s mission to develop first-in-class immunomodulatory drugs and I look forward to collaborating with the management and fellow Board members." Contacts ENTEROMEMEDIA RELATIONSGuillaume BayreHead of External CommunicationsTel: +33 (0)1 76 21 58 15communication@enterome.comLifeSci Advisors LLCAshley R. Robinson (US)+1 617 430 7577arr@lifesciadvisors.comSandya von der Weid (Europe)+41 78 680 05 38svonderweid@lifesciadvisors.com About Enterome Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Enterome’s first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones, or cytokines. The company’s two pipelines of drug candidates include: OncoMimics™ peptides, a pipeline of peptide-based immunotherapies. Lead candidate, EO2401, is in Phase 2 clinical trials in patients with glioblastoma and adrenal tumors and has demonstrated clinical proof of concept. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphomas, and has demonstrated a good safety profile with first signs of efficacy. EO4010 is in clinical development for third-line colorectal cancer and EO2040 is in a Phase 2 trial in patients suffering from colorectal cancer with ctDNA-defined, minimal residual disease.EndoMimics™ peptides, a pipeline of next generation bioactives acting like human hormones or cytokines, are being developed in collaboration with Nestlé Health Science, for food allergies and inflammatory bowel disease (IBD). The lead candidate, EB1010, is expected to enter clinical development in 2024. Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships. For more information, please visit the company’s website at: www.enterome.com

Phase 2Executive ChangeImmunotherapyAcquisition

08 Dec 2023

·www.fiercepharma.com

Fierce Pharma Asia—WuXi Bio's plunge; Daiichi-Novartis $182M settlement; Merck KGaA's Abbisko deal

WuXi Biologics' stock slide, Novartis and Daiichi Sankyo's settlement, and Merck KGaA and Abbisko's licensing deal made our news this week. WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute. Merck KGaA linked up with China's Abbisko Therapeutics on a phase 3 joint tumor med. And more. 1. Contract manufacturing giant WuXi Bio's stock plummets as it warns of $400M revenue miss WuXi Biologics’ stock price plummeted about 24% Monday after the CDMO giant said it expects to miss this year’s revenue target by around $400 million. The company pointed to an industrywide downturn in COVID-related sales and challenges in biotech funding. The biologics manufacturer views the first half of 2024 as its darkest hours, with a positive turnaround in the second half of next year. 2. Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case Novartis has agreed to pay $182 million to settle a patent dispute with Daiichi Sankyo. The case centers around Novartis’ melanoma drug Tafinlar. Daiichi’s former subsidiary Plexxikon, which developed rival BRAF drug Zelboraf, alleged that Tafinlar was made possible only because of discussions with Plexxikon about a partnership that never came to fruition. 3. Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront Merck KGaA paid $70 million upfront to license greater China rights to Abbisko Therapeutics’ phase 3 candidate for tenosynovial giant cell tumor, a benign tumor of the joint. Development is underway to test the CSF-1R inhibitor, pimicotinib, in graft-versus-host disease and solid tumors. Merck has an option to expand the deal to other geographies. 4. Novartis expands radiotherapy manufacturing network with $85M plant in China Novartis has unveiled a plan to build a new radiotherapy manufacturing facility in China with an investment of about $85 million. The new plant, located in Haiyan about 60 miles from Shanghai, is expected to be operational for local production in 2026. The Chinese project adds to Novartis’ existing radiotherapy facilities in Italy, Spain and the U.S. 5. High-flying Fujifilm splashes $200M to beef up cell therapy capacity Fujifilm plans to spend $200 million between Fujifilm Cellular Dynamics and Fujifilm Diosynth Biotechnologies to expand its cell therapy capabilities. The former subsidiary, focused on human induced pluripotent stem cells, will get a new headquarters in Madison, Wisconsin; and the latter CDMO will expand an existing site in Thousand Oaks, California. 6. South Africa's Aspen expands reach with $100M buy of Sandoz's Chinese business Sandoz is selling its China business to South Africa’s Aspen Pharmacare for about $100 million, with about $20 million tied to the future performance of Sandoz’s pipeline products. Aspen expects the deal to add about $96 million in annual sales, with such products such as the synthetic hormone injectable Sandostatin. 7. Tang Capital’s Concentra back with another buyout offer, this time for LianBio LianBio has rejected an unsolicited buyout proposal by Tang Capital Partners’ Concentra Biosciences, saying the deal terms undervalue the company. LianBio, built on a business model of bringing innovative drugs to China and other Asian markets, recently launched a strategic review and sold certain Asian rights to mavacamten to Bristol Myers Squibb for $350 million. Other News of Note: 8. FDA recommends avoiding plastic syringes made in China amid safety investigation 9. With J&J settlement, Samsung Bioepis and Sandoz lock down Stelara biosimilar license 10. FDA posts a flurry of voluntary drug recalls by Teva, Glenmark, Apotex and VistaPharm 11. Coya taps familiar friend Dr. Reddy’s to commercialize ALS med

AcquisitionPhase 3Cell TherapyPatent Infringement

08 Dec 2023

·www.biospace.com

Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case

Pictured: Building with Daiichi Sankyo sign/photo courtesy of Daiichi Sankyo Plexxikon, a subsidiary of Daiichi Sankyo, and Novartis have settled a patent infringement suit against over the sale of Novartis’ cancer drug Tafinlar in the U.S. Under the settlement announced Wednesday, Plexxikon will receive an estimated lump sum payment of $182 million. The settlement will result in the dismissal of Novartis’ appeal and “full satisfaction of the judgment entered against Novartis.” The U.S. District Court for Northern California issued an order in 2021 sustaining a jury verdict in favor of Plexxikon, which found that Tafinlar had infringed upon several of Plexxikon’s U.S. patents. The court had initially ordered Novaritso to pay over $177 million in damages and a 9% royalty on U.S. drug sales until the patents expire. Novartis decided to appeal the case in 2022 in the U.S. Court of Appeals for the Federal Circuit. Tafinlar, in combination with Mekinist, brought in over $480 million in sales for Novartis in the third quarter of 2023. Plexxikon’s case claimed that its patents, which are for compounds that reduce cancer cell growth, were developed in 2005 which the company eventually co-developed the melanoma drug Zelboraf with Roche. In 2011, Plexxikon had received approval for Zelboraf. GSK traded the drug to Novartis in 2015, applied its Tafinlar patents in 2008 and secured approval in 2013. However, in 2017, Plexxikon filed suit against Novartis, claiming the Swiss pharma had infringed on two patents that covered Zelboraf. Novartis countered that Plexxikon’s patents were invalid due to the three GSK compounds that preceded the patents. However, a jury decided that Novartis could not prove these claims. Daiichi Sankyo said it will receive a lump sum payment of around 26.4 billion Yenfrom Novartis. The Japanese pharma will mark this as “temporary income” on its financial disclosure sheets. Daiichi Sankyo also noted that the settlement has not been put into its economic forecasts for its fiscal year ending on March 31, 2024. Plexxikon was shut down in 2022 as Daiichi Sankyo chose to focus on developing its antibody-drug conjugates. Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

Patent InfringementDrug Approval

100 Deals associated with Vemurafenib

External Link

KEGG	Wiki	ATC	Drug Bank
D09996	Vemurafenib	L01XE15	DB08881

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
BRAF V600 mutation-positive Melanoma	EU	Roche Registration GmbH	17 Feb 2012
BRAF V600 mutation-positive Melanoma	IS	Roche Registration GmbH	17 Feb 2012
BRAF V600 mutation-positive Melanoma	LI	Roche Registration GmbH	17 Feb 2012
BRAF V600 mutation-positive Melanoma	NO	Roche Registration GmbH	17 Feb 2012
Melanoma	US	Hoffmann-La Roche, Inc.	17 Aug 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anaplastic Thyroid Carcinoma	Phase 3	GB	Hoffmann-La Roche Ltd.	01 Mar 2023
Anaplastic Thyroid Carcinoma	Phase 3	GB	Cancer Research UK	01 Mar 2023
BRAF V600 mutation-positive Neoplasms	Phase 3	GB	Cancer Research UK	01 Mar 2023
BRAF V600 mutation-positive Neoplasms	Phase 3	GB	Hoffmann-La Roche Ltd.	01 Mar 2023
Colorectal Cancer	Phase 3	GB	Cancer Research UK	01 Mar 2023
Colorectal Cancer	Phase 3	GB	Hoffmann-La Roche Ltd.	01 Mar 2023
Erdheim-Chester Disease	Phase 3	GB	Cancer Research UK	01 Mar 2023
Erdheim-Chester Disease	Phase 3	GB	Hoffmann-La Roche Ltd.	01 Mar 2023
Glioma	Phase 3	GB	Cancer Research UK	01 Mar 2023
Glioma	Phase 3	GB	Hoffmann-La Roche Ltd.	01 Mar 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03498521 (CUPISCO, CTgov)	Phase 2	Neoplasms	528	platinum (Molecularly-Guided Therapy MGT) Category 1)	ivpvjcbtlr(ryjzlxkijh) = cekibsqjoy mvlehueobp (qurccvybqf, siwxtapabc - qzxyfeqwrq) View more	-	14 Jun 2024
				platinum (Chemotherapy Category 1)	ivpvjcbtlr(ryjzlxkijh) = vksorouiqq mvlehueobp (qurccvybqf, tpnhiheqxn - uddtfvwgnc) View more
HCL-PG04 (EHA2024) Manual	Phase 2	Hairy Cell Leukemia BRAF V600E	26	Obinutuzumab +/- VEMURAFENIB	dlamwgowyr(kflzrxsgue) = janrnesiec ztmtpqnpeg (qdycgfeazn ) View more	Positive	14 May 2024
NCT03625141 (TRICOTEL, CTgov)	Phase 2	Neoplasm Metastasis \| Metastatic melanoma \| BRAF V600 mutation-positive Melanoma	80	Atezolizumab+Cobimetinib+Vemurafenib (Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib)	xyyyssseln(crlacagqhx) = crefxnxaxf ooopcazlaq (yfkdbmirwd, emvrpjxksj - efrajqatgp) View more	-	08 Feb 2024
				Atezolizumab+Cobimetinib (Cohort 1- Cobimetinib and Atezolizumab)	jyzbqtrgth(ecfcnofmwv) = ewzeyhdvpu nytfdfckkg (ljldiddrkv, ksszdhwibi - bipnmkuvji) View more
HCL-PG03R (ASH2023)	Not Applicable	Hairy Cell Leukemia	35	Vemurafenib Plus Rituximab (V+R)	uvofodbjwz(sqpcvyheyi) = rbrijcwhpb lqqmrcaaca (caszhyzxrg ) View more	Positive	10 Dec 2023
NCT03781219 (ESMO2023) Manual	Phase 1	Advanced Malignant Solid Neoplasm BRAF V600 mutation	72	tunlametinib 9mg + vemurafenib 720mg	qxpdrcpnlv(kgrwzzpeqx) = The most common AE were CK elevation, anemia and rash which were predominantly grade 1/2. rqzmrdtupi (apxtkcjfid )	Positive	23 Oct 2023
				Tunlametinib + Vemurafenib (NSCLC)
ESMO2023 Manual	Not Applicable	BRAF mutation positive Melanoma First line BRAF	583	Vemurafenib + Cobimetinib	vhwaozdzlt(fkpyvzgpvs) = earuzabmsz sgjoloqgbz (stvrioiznr ) View more	Positive	22 Oct 2023
				Dabrafenib + Trametinib	vhwaozdzlt(fkpyvzgpvs) = sctblhpcxf sgjoloqgbz (stvrioiznr ) View more
NCT05019534 (ESMO2023) Manual	Phase 1	BRAF V600E mutant Colorectal Cancer Microsatellite Stable (MSS) \| BRAF V600E mutation	12	Vemurafenib+Camrelizumab+cetuximab	wknfcmyjvy(uqflvqifdq) = grade 1-2 treatment-related AEs occurred in 12 patients (100.0%). Grade 1-2 AEs included drug-related rash (75.0%), articular pain (75.0%), reactive capillary proliferation disease (66.7%), anemia (53.3%), muscular pain (41.7%), mucosal hemorrhage (41.7%), fatigue (25.0%), and mouth ulcers (16.7%) pkoqigebqe (bpnwafhsdt ) View more	Positive	22 Oct 2023
NCT05540951 (ESMO2023) Manual	Phase 3	BRAF V600E mutant Colorectal Cancer First line BRAF V600E	67	Vemurafenib+Irinotecan+Cetuximab	kagrdwiocg(mjsadpjfhk) = twzggsomgk iluyqzsllh (nrntoqthky ) View more	Positive	22 Oct 2023
				Bevacizumab+ chemotherapy	kagrdwiocg(mjsadpjfhk) = wflkapdchj iluyqzsllh (nrntoqthky ) View more
NCT03220035 (CTgov)	Phase 2	Refractory Central Nervous System Lymphoma \| germ cell cancers \| Ependymoma ... View more	4	Laboratory Biomarker Analysis+Vemurafenib	cedryovssr(hgdfezhyhu) = qqvahbkddy rjstjvtvih (vltqkeywwc, dmcuwkhori - fxdqffccfs) View more	-	13 Sep 2023
ASCO2023	Not Applicable	Colorectal Cancer	185	Vemurafenib + Irinotecan + Cetuximab	dehnyefeqq(ayorehkgcs) = lbwegjsnyx hftwvarcsm (lqqncjwgqx ) View more	Positive	31 May 2023
				Cetuximab + Irinotecan	-

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis